文献速递膀胱癌与上尿路尿路上皮癌

两周期新辅助化疗改善高危上尿路尿路上皮癌生存

Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
PubMed 文献 · BJU Int · 2020-09-28

该回顾性研究比较两周期新辅助化疗后肾输尿管切除术与直接手术在高危cN0M0上尿路尿路上皮癌中的疗效,发现新辅助化疗组病理降期率更高、淋巴血管侵犯更少,5年总生存、癌症特异性生存和无复发生存均显著更优,且局限性疾病(≤cT2)患者亦获益。

要点

  • 两周期新辅助化疗显著提高高危cN0M0上尿路尿路上皮癌的5年总生存(79% vs 53%)。
  • 新辅助化疗组病理降期率更高(48% vs 22%),淋巴血管侵犯更少(29% vs 46%)。
  • 局限性疾病(≤cT2)患者同样从新辅助化疗中获得总生存获益(P=0.019)。

核心结论

  • 两周期新辅助化疗可改善高危cN0M0上尿路尿路上皮癌患者的生存,包括局限性疾病患者。

研究设计与样本

  • 回顾性分析2005-2019年于Fujita Health University接受新辅助化疗后手术的高危cN0M0上尿路尿路上皮癌患者117例,与匹配的初始手术对照组67例比较。

主要发现

  • 新辅助化疗组病理降期率显著高于对照组(48% vs 22%,P=0.008),淋巴血管侵犯率显著更低(29% vs 46%,P=0.045)。
  • 新辅助化疗组5年总生存(79% vs 53%,P=0.003)、5年癌症特异性生存(84% vs 66%,P=0.008)和5年无复发生存(80% vs 61%,P=0.001)均显著优于对照组。
  • 局限性疾病(≤cT2)患者中新辅助化疗的总生存获益仍显著(P=0.019)。
  • 多因素分析确定淋巴血管侵犯、新辅助化疗和病理降期为总生存的独立预测因素。

关键数值与推荐

  • 病理降期率:新辅助化疗组48% vs 对照组22%(P=0.008)。
  • 淋巴血管侵犯率:新辅助化疗组29% vs 对照组46%(P=0.045)。
  • 5年总生存:新辅助化疗组79% vs 对照组53%(P=0.003)。
  • 5年癌症特异性生存:新辅助化疗组84% vs 对照组66%(P=0.008)。
  • 5年无复发生存:新辅助化疗组80% vs 对照组61%(P=0.001)。

临床怎么用

  • 对高危cN0M0上尿路尿路上皮癌患者,可考虑两周期新辅助化疗后行肾输尿管切除术。
  • 局限性疾病(≤cT2)患者亦可从新辅助化疗中获益,不应仅因分期较早而排除。
  • 淋巴血管侵犯与更差生存相关,新辅助化疗后淋巴血管侵犯状态可用于风险分层。

局限性

  • 回顾性研究设计,样本量有限(新辅助化疗组117例,对照组67例)。
  • 需更大样本多中心前瞻性研究比较短程新辅助化疗后手术与单纯手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of two cycles of neoadjuvant chemotherapy (NAC) in patients who underwent nephroureterectomy for high-risk cN0M0 upper tract urothelial carcinoma (UTUC), and to evaluate the efficacy of NAC in patients with localised disease (≤cT2). PATIENTS AND METHODS: We retrospectively analysed patients with high-risk cN0M0 UTUC who received NAC followed by surgery, compared with a matched cohort who underwent initial surgery at Fujita Health University during 2005-2019. Baseline and tumour characteristics, overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were compared between the cohorts. Cox proportional hazards models were used to identify predictors of survival. RESULTS: There were 117 and 67 patients in the study group and the control group, respectively. Significantly higher pathological downstaging (pDS) and lower lymphovascular invasion (LVI) were observed in the study group than in the control group (48% vs 22%, P = 0.008 and 29% vs 46%, P = 0.045, respectively). The NAC group had significantly better 5-year OS (79% vs 53%, P = 0.003), 5-year CSS (84% vs 66%, P = 0.008), and 5-year RFS (80% vs 61%, P = 0.001) than the control group. The OS benefit of NAC was observed even in patients with localised (≤cT2) disease (P = 0.019). Patients with LVI showed significantly worse CSS both in pathologically locally advanced (≥pT3) and in localised (≤pT2) tumours (P = 0.048 and P = 0.018, respectively). Multivariate analysis identified LVI, NAC, and pDS as independent predictors of OS. Male sex and post-NAC LVI were identified as predictors of worse survival in patients who underwent NAC. CONCLUSIONS: Two cycles of NAC improved the survival of patients with high-risk UTUC, even in patients with localised disease. Although two cycles of NAC appear to be effective in cN0M0 high-risk UTUC including localised disease, additional larger sample size multicentre prospective studies comparing short-course NAC regimens followed by surgery and surgery alone are required.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Zennami K, Sumitomo M, Takahara K, et al. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma. BJU Int. 2020. PMID: 32896105. doi:10.1111/bju.15230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。